**Lisa Warsinger Martin, MD, FACC**
Associate Prof. of Medicine-retired, emeritus pending 2022

Printed as of 11/19/2026

# Disclosures

## Personal Commercial (7)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|---|---|
| *Self* | | | |
| Abbott, Bristol-Meyers-Squibb, Crisper,Cytokinetics,Editas Medicine, Intuitive Surgical, Johnson &Johnson, Merck, Moderna, Proctor & Gamble, C4 Theraputics | Stock | None ($0) | *General Cardiology Other* |
| Amarin Reduce-IT trial - EPA Omega 3 randomized trial for triglycerides-finished > 12 months ago | Research/Research Grants | Modest (< $5,000) | *Prevention* |
| Anthera - Cleveland Clinic trial - study site- finished >12 months ago | Research/Research Grants | Modest (< $5,000) | *General Cardiology* |
| Novartis - Harvard Hospitals- Brigham, I think- finished > 12 months ago | Research/Research Grants | Modest (< $5,000) | *General Cardiology* |
| Novartis ASTRONAUT multicenter trial finished >12 months ago 2013 Aliskiren | Research/Research Grants | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| Pfizer finished >12 months ago | Research/Research Grants | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| ROCHE -Daletrapib trial finished >12 months ago | Research/Research Grants | Modest (< $5,000) | *General Cardiology Prevention* |

## Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

## Personal Organizational or Other Non-Commercial (4)

| Non-Commercial Enity Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|---|---|
| *Self* | | | |
| Geroge Washington University Hospital Pharmacy Department<br>*† GWUH Pharmacy department -2019 last event* | Other - *Speaker at symposium* | Modest (< $5,000) | *Prevention* |
| National Cancer Institute of Canada Clinical trials Group-NCIC | Research/Research Grants | Significant (>= $5,000) | *Prevention* |
| NIH- WARCEF Warfarin Vs Aspirin<br>*† N/A* | Research/Research Grants | Modest (< $5,000) | *Heart Failure and Cardiomyopathies* |
| NIH- Women's Health Initiative<br>*† NO* | Research/Research Grants | Significant (>= $5,000) | *Prevention General Cardiology* |

## Clinical Trial Enroller (0)

No disclosures on record

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (0)

No disclosures on record

*† Commercial Funding Source | ‡ Trial Name*

# Agreement

**Certified Education Attestation** | Signed on 8/31/2022
*URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement*

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 8/31/2022
*URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement*

**Embargo** | Signed on 8/31/2022
*URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement*

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.